Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
Submitted by
admin
on October 11, 2008 - 12:02pm
Source:
Medical News Today
Headline:
FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
Do Not Allow Advertisers to Use My Personal information
